METHOD FOR CORRECTION OF NEUROTROPHILIC CHANGES IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AFTER CORONAVIRUS INFECTION Russian patent published in 2024 - IPC A61F9/00 G01N33/49 A61K31/194 A61K31/455 A61K31/525 A61P27/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and is intended for correction of neurotrophic changes in retina in patients with primary open-angle glaucoma suffered coronavirus infection. Brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) level, severity of oxidative stress (OS) by amount of peroxides and malondialdehyde (MDA) in blood plasma, state of antioxidant system by peroxide decomposed by antioxidants per litre of serum and coenzyme Q10 are determined in blood serum. If BDNF is less than 24.19 ng/ml, CNTF is more than 1.77 pg/ml, the amount of peroxides is more than 180 mcmol/l, the amount of peroxide decomposed by antioxidants per litre of serum is less than 320 mcmol/l, MDA is more than 4.27 nmol/l, coenzyme Q10 less than 1.1, Cytoflavin solution 10 ml in 0.9% saline 200 ml is administered intravenously daily for 10 days, then 2 tablets are orally introduced 2 times day for 25 days.

EFFECT: method enables improving the functional state of the retina and its neuronal activity, reducing the risk of oxidative stress and neurodegeneration ensured by early diagnosis of neurotrophic changes in the retina and pathogenetic treatment with the complex preparation Cytoflavin.

1 cl, 3 ex